Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder

Abstract

Immune dysregulation is implicated in major depressive disorder (MDD), but its links to clinical features and in vivo brain phenotypes remain uncertain. We examined ten plasma biomarkers in 36 unmedicated MDD patients and 48 control participants using high-sensitivity immune profiling at baseline, alongside PET/MR imaging of brain serotonin transporter (SERT) binding and regional structural measures. Patients underwent three months of antidepressant treatment and were followed up with MR imaging. Glial fibrillary acidic protein (GFAP) was higher in MDD patients ({beta} = 0.66, 95% CI 0.22 - 1.11), and interleukin-33 (IL-33) correlated with subcortical volumes across all participants ({beta} = 0.22, 95% CI 0.07 - 0.38). No marker correlated with SERT binding or cortical thickness after correction, and neither SERT binding nor brain structural measures differed by diagnosis. In the longitudinal analysis, interleukin-13 (IL-13) was associated with greater antidepressant response during first-line treatment with escitalopram ({beta} = 1.09, 95% CI 0.56 - 1.61). IL-15 and IL-13 showed nominal associations with hippocampal volume increase after treatment. These findings suggest astroglial involvement in MDD and that peripheral immune states relate to subcortical brain structure. IL-13 is a candidate prognostic marker of response to selective serotonin reuptake inhibitors. Its tentative association with longitudinal changes in hippocampal volume suggests that immune processes in MDD may be related to both the capacity for clinical improvement and brain structural plasticity during treatment.

Peripheral molecular signatures of major depressive disorder: a systematic review of blood-derived biomarkers for diagnosis, stratification, and treatment response.
M S Jayanth, G Sindhu, Hariharan Murugadoss +3
BMC psychiatry5 Aug 2026Peer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMCPMC
Peripheral Brain-Derived Neurotrophic Factor Changes and Clinical Response to Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder: A Systematic Review.
Christian David Galindo, Guillermo Jemar, Isabel Carolina Osorio +5
Cureus7 Nov 2026Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
CSF Alzheimer's Disease Biomarkers in Relation to Functional Status and Tofersen Treatment Response in ALS
F. Eberle, S. Bersen, F. Rachel +3
medRxiv26 Oct 2026PreprintAll rights reservedFull textNeurologymedRxiv
Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders
Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz
CNS Spectrums28 Sep 2026Peer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMC
Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.
Alessandro Castiglione, Barbro Kjellström, Göran Rådegran +1
European heart journal. Case reports26 Oct 2026Peer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMCPMC

Cite

BibTeX RIS

BibTeX

@misc{eggerstorfer2026peripheral,
  title = {{Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder}},
  author = {B. Eggerstorfer and P. Altmann and M. Murgas and M. Ponleitner and G. M. Godbersen and M. Klöbl and J. Unterholzner and L. R. Silberbauer and C. Vraka and C. Philippe and L. Nics and A. Hahn and M. Hacker and G. Gryglewski and R. Lanzenberger},
  howpublished = {medRxiv},
  year = {2026},
  month = nov,
  doi = {10.64898/2026.11.03.26367072},
  url = {https://www.medrxiv.org/content/10.64898/2026.11.03.26367072v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
AU  - B. Eggerstorfer
AU  - P. Altmann
AU  - M. Murgas
AU  - M. Ponleitner
AU  - G. M. Godbersen
AU  - M. Klöbl
AU  - J. Unterholzner
AU  - L. R. Silberbauer
AU  - C. Vraka
AU  - C. Philippe
AU  - L. Nics
AU  - A. Hahn
AU  - M. Hacker
AU  - G. Gryglewski
AU  - R. Lanzenberger
PY  - 2026
DA  - 2026/11/03
PB  - medRxiv
DO  - 10.64898/2026.11.03.26367072
UR  - https://www.medrxiv.org/content/10.64898/2026.11.03.26367072v1
AB  - Immune dysregulation is implicated in major depressive disorder (MDD), but its links to clinical features and in vivo brain phenotypes remain uncertain. We examined ten plasma biomarkers in 36 unmedicated MDD patients and 48 control participants using high-sensitivity immune profiling at baseline, alongside PET/MR imaging of brain serotonin transporter (SERT) binding and regional structural measures. Patients underwent three months of antidepressant treatment and were followed up with MR imaging. Glial fibrillary acidic protein (GFAP) was higher in MDD patients ({beta} = 0.66, 95% CI 0.22 - 1.11), and interleukin-33 (IL-33) correlated with subcortical volumes across all participants ({beta} = 0.22, 95% CI 0.07 - 0.38). No marker correlated with SERT binding or cortical thickness after correction, and neither SERT binding nor brain structural measures differed by diagnosis. In the longitudinal analysis, interleukin-13 (IL-13) was associated with greater antidepressant response during first-line treatment with escitalopram ({beta} = 1.09, 95% CI 0.56 - 1.61). IL-15 and IL-13 showed nominal associations with hippocampal volume increase after treatment. These findings suggest astroglial involvement in MDD and that peripheral immune states relate to subcortical brain structure. IL-13 is a candidate prognostic marker of response to selective serotonin reuptake inhibitors. Its tentative association with longitudinal changes in hippocampal volume suggests that immune processes in MDD may be related to both the capacity for clinical improvement and brain structural plasticity during treatment.
ER  -

Abstract

Related

Cite